{
  "protocol": {
    "protocol_number": "NVX-1218.22",
    "protocol_name": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of NovaPlex-450 in Combination with Standard Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer",
    "short_title": "NovaPlex-450 in Advanced NSCLC",
    "sponsor": {
      "name": "NexaVance Therapeutics Inc.",
      "legal_entity": "NexaVance Therapeutics Inc.",
      "address": "1250 Innovation Drive, Cambridge, MA 02139, USA",
      "contact_name": "Dr. Sarah Mitchell",
      "contact_email": "clinical.trials@nexavance.com",
      "contact_phone": "+1-617-555-0142"
    },
    "phase": "III",
    "indication": "Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "study_type": "Interventional",
    "design": "Randomized, Double-Blind, Placebo-Controlled, Parallel Group",
    "therapeutic_area": "Oncology",
    "study_drug": {
      "investigational_product": "NovaPlex-450",
      "drug_class": "PD-L1/CTLA-4 Dual Checkpoint Inhibitor",
      "dosage_form": "Intravenous Infusion",
      "dose": "450 mg Q3W (every 3 weeks)",
      "route": "Intravenous"
    },
    "objectives": {
      "primary": "To evaluate progression-free survival (PFS) in patients treated with NovaPlex-450 plus chemotherapy versus placebo plus chemotherapy",
      "secondary": [
        "Overall survival (OS)",
        "Objective response rate (ORR)",
        "Duration of response (DoR)",
        "Safety and tolerability",
        "Quality of life (QoL) assessments"
      ]
    },
    "endpoints": {
      "primary": "Progression-Free Survival (PFS) by RECIST 1.1",
      "secondary": [
        "Overall Survival (OS)",
        "Objective Response Rate (ORR)",
        "Duration of Response",
        "Incidence of Adverse Events",
        "Changes in EORTC QLQ-C30 scores"
      ]
    },
    "treatment_arms": [
      {
        "arm_id": 1,
        "name": "NovaPlex-450 + Chemotherapy",
        "description": "NovaPlex-450 450mg IV Q3W + Carboplatin/Pemetrexed",
        "planned_subjects": 200
      },
      {
        "arm_id": 2,
        "name": "Placebo + Chemotherapy",
        "description": "Placebo IV Q3W + Carboplatin/Pemetrexed",
        "planned_subjects": 200
      }
    ],
    "inclusion_criteria": [
      "Age ≥18 years",
      "Histologically or cytologically confirmed NSCLC",
      "Stage IV disease or recurrent NSCLC not amenable to curative therapy",
      "ECOG Performance Status 0-1",
      "PD-L1 expression ≥50% by IHC",
      "Measurable disease per RECIST 1.1",
      "Adequate organ function: ANC ≥1.5 x 10^9/L, Platelets ≥100 x 10^9/L, Hemoglobin ≥9 g/dL",
      "Adequate hepatic function: Total bilirubin ≤1.5 x ULN, AST/ALT ≤2.5 x ULN",
      "Adequate renal function: Creatinine clearance ≥50 mL/min",
      "Negative pregnancy test for women of childbearing potential",
      "Written informed consent"
    ],
    "exclusion_criteria": [
      "Prior therapy with PD-1/PD-L1 or CTLA-4 inhibitors",
      "Active CNS metastases",
      "Active autoimmune disease requiring systemic treatment",
      "History of severe hypersensitivity to monoclonal antibodies",
      "Active infection requiring systemic therapy",
      "Known HIV, HBV, or HCV infection",
      "Pregnant or breastfeeding",
      "QTcF >470 msec on screening ECG"
    ],
    "study_duration": {
      "treatment_period": "24 weeks",
      "follow_up_period": "4 weeks",
      "total_duration": "28 weeks",
      "survival_follow_up": "Until death or study closure"
    },
    "visit_schedule": [
      {
        "visit_number": 1,
        "visit_name": "Screening",
        "day": -14,
        "window_lower": -21,
        "window_upper": -1,
        "assessments": ["Informed Consent", "Demographics", "Medical History", "Vital Signs", "Physical Exam", "ECG", "Labs", "Tumor Assessment", "PD-L1 Testing"]
      },
      {
        "visit_number": 2,
        "visit_name": "Baseline/Randomization",
        "day": 1,
        "window_lower": 0,
        "window_upper": 0,
        "assessments": ["Randomization", "Vital Signs", "Labs", "Pregnancy Test", "QoL Questionnaire", "First Dose"]
      },
      {
        "visit_number": 3,
        "visit_name": "Week 3 (Cycle 1)",
        "day": 21,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "AE Assessment", "Conmed Review", "Dose 2"]
      },
      {
        "visit_number": 4,
        "visit_name": "Week 6 (Cycle 2)",
        "day": 42,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "AE Assessment", "Conmed Review", "Dose 3"]
      },
      {
        "visit_number": 5,
        "visit_name": "Week 9 (Cycle 3)",
        "day": 63,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "Tumor Assessment", "AE Assessment", "ECG", "QoL", "Dose 4"]
      },
      {
        "visit_number": 6,
        "visit_name": "Week 12 (Cycle 4)",
        "day": 84,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "AE Assessment", "Conmed Review", "Dose 5"]
      },
      {
        "visit_number": 7,
        "visit_name": "Week 15 (Cycle 5)",
        "day": 105,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "AE Assessment", "Conmed Review", "Dose 6"]
      },
      {
        "visit_number": 8,
        "visit_name": "Week 18 (Cycle 6)",
        "day": 126,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "Tumor Assessment", "AE Assessment", "ECG", "QoL", "Dose 7"]
      },
      {
        "visit_number": 9,
        "visit_name": "Week 21 (Cycle 7)",
        "day": 147,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "AE Assessment", "Conmed Review", "Dose 8"]
      },
      {
        "visit_number": 10,
        "visit_name": "Week 24 (End of Treatment)",
        "day": 168,
        "window_lower": -3,
        "window_upper": 3,
        "assessments": ["Vital Signs", "Labs", "Tumor Assessment", "AE Assessment", "ECG", "QoL", "Final Dose"]
      },
      {
        "visit_number": 11,
        "visit_name": "Follow-up (Week 28)",
        "day": 196,
        "window_lower": -7,
        "window_upper": 7,
        "assessments": ["Vital Signs", "Labs", "Tumor Assessment", "AE Assessment", "Survival Status"]
      }
    ],
    "sample_size": {
      "planned_total": 400,
      "per_arm": 200,
      "number_of_sites": 40,
      "enrollment_period": "24 months",
      "study_start_date": "2024-03-15",
      "estimated_completion_date": "2026-09-15"
    },
    "regulatory": {
      "ind_number": "IND-145892",
      "eudract_number": "2024-001234-56",
      "ethics_approval": "Required at all sites",
      "data_monitoring_committee": true,
      "gcp_compliance": "ICH-GCP E6(R2)"
    }
  }
}
